アフターアワーズ： 2.16 -0.010 -0.46%

Serina Therapeutics Inc (SER)

概要ニュース株価時系列ディスカッション予測

Serina Therapeutics Inc (SER) 最新ニュース

Serina Therapeutics Inc (SER)

Serina Therapeutics Inc (SER) 最新ニュース

Enterprise value to EBIT forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView

Serina Therapeutics (SER) Stock Forecast and Price Target 2026 $SER - MarketBeat

SER Initiated Coverage by BTIG -- Rating Set to Buy with $8.00 P - GuruFocus

Serina Therapeutics Price Target Announced at $8.00/Share by BTIG - Moomoo

BTIG Initiates Serina Therapeutics(SER.US) With Buy Rating, Announces Target Price $8 - Moomoo

BTIG initiates Serina Therapeutics stock with buy on drug delivery platform - Investing.com Canada

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - marketscreener.com

Enterprise value to EBITDA forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView

Enterprise value to revenue forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView

Price to sales forward of Serina Therapeutics, Inc. – AMEX:SER - TradingView

Number of shareholders of Serina Therapeutics, Inc. – AMEX:SER - TradingView

Serina Therapeutics, Inc. Actuals & Estimates (AMEX:SER) - TradingView

SER Forecast — Price Target — Prediction for 2027 - TradingView

2BO Forecast — Price Target — Prediction for 2027 - TradingView

Serina Therapeutics, Inc. Actuals & Estimates (BOATS:SER) - TradingView

Serina Therapeutics Shareholders Approve Expanded Equity and Governance - TipRanks

Serina Therapeutics (NYSE: SER) holders back major share and equity plan increases - Stock Titan

Form 4 Serina Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Serina Therapeutics director Jay Venkatesan buys $1,048 in common stock By Investing.com - Investing.com Australia

Serina Therapeutics director Jay Venkatesan buys $1,048 in common stock - Investing.com

Serina (SER) director converts preferred into common and buys more stock - Stock Titan

Serina Therapeutics (SER) director boosts equity via conversions and new warrants - Stock Titan

Serina Therapeutics (SER) director receives 15,250 stock options at $1.98 - Stock Titan

Serina Therapeutics (SER) director granted 15,250 stock options at $1.98 strike - Stock Titan

Serina Therapeutics (SER) Stock Price, News & Analysis $SER - MarketBeat

Serina Therapeutics Inc (SER) Valuation: PE, PB & Fair Value Analysis - TradingKey

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today? - MSN

Serina Therapeutics Inc (SER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Serina Therapeutics Inc (SER) Institutional Confidence - TradingKey

Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

SER: All proposals, including director elections and share increase, were approved without stockholder questions - TradingView

SER: All eight proposals, including board elections and share increase, were approved without stockholder questions - TradingView

Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

$Serina Therapeutics (SER.US)$ patiently waiting! - Moomoo

Insider Buying: Karen Wilson Acquires Shares of Serina Therapeutics Inc (SER) - GuruFocus

Serina Therapeutics director Karen Wilson buys $17,749 common stock By Investing.com - Investing.com India

Serina Therapeutics director Karen Wilson buys $17,749 common stock - Investing.com UK

Director Karen J. Wilson boosts Serina (SER) stake with 10,100-share purchase - Stock Titan

Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Losses Wider Than Expected as Pre-Revenue Biotech Continues Clinical DevelopmentDownward Estimate Revision - newsline.com

Serina Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

Serina Therapeutics (SER) Gains 4% as It Tests Key Resistance at $1.90BPI Bull Confirmed - newsline.com

Serina Therapeutics (SER) Tests Key Support After Modest DeclineSafe Entry Stocks - newsline.com

SER Q1 2026 Earnings: EPS Misses Estimates as Development-Focused Biotechnology Firm Continues Pipeline ProgressGuidance Accuracy Score - dars.gov.et

SER News | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill

[EFFECT] Serina Therapeutics, Inc. SEC Filing - Stock Titan

SERに似た銘柄